Rethinking Antigen Source: Cancer Vaccines Based on Whole Tumor Cell/tissue Lysate or Whole Tumor Cell

Diao, Lu; Liu, Mi

doi:10.1002/advs.202300121

Cited by 22 publications

(3 citation statements)

References 235 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Leukemia‐derived DCs and monocyte‐derived DCs (Mo‐DCs) are the two primary DC types used in DC vaccines. Phase I, II, and III clinical trials have investigated DC cancer vaccines because it is feasible to cultivate DCs in enough quantities 20–22 …”

Section: Cancer Vaccine Platform Typesmentioning

confidence: 99%

Recent advances in mRNA‐based vaccine for cancer therapy; bench to bedside

Kenoosh,

Pallathadka,

Hjazi

et al. 2024

Cell Biochemistry & Function

View full text Add to dashboard Cite

The messenger RNA (mRNA) vaccines have progressed from a theoretical concept to a clinical reality over the last few decades. Compared to conventional vaccination methods, these vaccines have a number of benefits, such as substantial potency, rapid growth, inexpensive production, and safe administration. Nevertheless, their usefulness was restricted up to now due to worries about the erratic and ineffective circulation of mRNA in vivo. Thankfully, these worries have largely been allayed by recent technological developments, which have led to the creation of multiple mRNA vaccination platforms for cancer and viral infections. The mRNA vaccines have been demonstrated as a powerful alternative to traditional conventional vaccines because of their high potency, safety and efficacy, capacity for rapid clinical development, and potential for rapid, low‐cost manufacturing. The paper will examine the present status of mRNA vaccine technology and suggest future paths for the advancement and application of this exciting vaccine platform as a common therapeutic choice.

show abstract

Section: Cancer Vaccine Platform Typesmentioning

confidence: 99%

Recent advances in mRNA‐based vaccine for cancer therapy; bench to bedside

Kenoosh,

Pallathadka,

Hjazi

et al. 2024

Cell Biochemistry & Function

View full text Add to dashboard Cite

show abstract

“…Moreover, traditional vaccines elicit humoral immunity, whereas cellular immunity mediated by the CD8 + cytotoxic T lymphocytes (CTLs) plays a key role in killing cancer cells for cancer vaccines ( 9 , 10 ). A variety of strategies have been developed to increase the efficacy of the vaccine by application of the whole-tumor lysate ( 11 ), coadministration of antigens with adjuvants ( 12 , 13 ), and formulation in carriers ( 14 ). Nanocarriers are recognized as promising delivery vehicles for cancer vaccines, which facilitate targeted delivery of antigens to essential immune organs and cell types ( 15 – 17 ).…”

Section: Introductionmentioning

confidence: 99%

Lymph-targeted high-density lipoprotein-mimetic nanovaccine for multi-antigenic personalized cancer immunotherapy

Liu,

Feng,

et al. 2024

Sci. Adv.

View full text Add to dashboard Cite

Cancer vaccines show huge potential for cancer prevention and treatment. However, their efficacy remains limited due to weak immunogenicity regarding inefficient stimulation of cytotoxic T lymphocyte (CTL) responses. Inspired by the unique characteristic and biological function of high-density lipoprotein (HDL), we here develop an HDL-mimicking nanovaccine with the commendable lymph-targeted capacity to potently elicit antitumor immunity using lipid nanoparticle that is co-loaded with specific cancer cytomembrane harboring a collection of tumor-associated antigens and an immune adjuvant. The nanoparticulate impact is explored on the efficiency of lymphatic targeting and dendritic cell uptake. The optimized nanovaccine promotes the co-delivery of antigens and adjuvants to lymph nodes and maintains antigen presentation of dendritic cells, resulting in long-term immune surveillance as the elevated frequency of CTLs within lymphoid organs and tumor tissue. Immunization of nanovaccine suppresses tumor formation and growth and augments the therapeutic efficacy of checkpoint inhibitors notably on the high-stemness melanoma in the mouse models.

show abstract

“…Whole tumor cell-based vaccines have recently been reviewed by other scholars, highlighting the advantages of using whole cancer cell-based immunization [35][36][37]. Whole-cell vaccinations demonstrate pan-spectra of tumor antigens inducing multi-clonal expansion of tumor-reactive T-cells, and they may overcome the heterogeneity of tumor cells.…”

Section: Introductionmentioning

confidence: 99%

Introduction of an Ultraviolet C-Irradiated 4T1 Murine Breast Cancer Whole-Cell Vaccine Model

Szebeni

Alföldi²,

Nagy³

et al. 2023

Vaccines

View full text Add to dashboard Cite

The advent of immunotherapy has revolutionized cancer treatments. However, the application of immune checkpoint inhibitors may entail severe side effects, with the risk of therapeutic resistance. The generation of chimeric antigen receptor (CAR) T-cells or CAR-NK cells requires specialized molecular laboratories, is costly, and is difficult to adapt to the rapidly growing number of cancer patients. To provide a simpler but effective immune therapy, a whole-cell tumor vaccine protocol was established based on ultraviolet C (UCV)-irradiated 4T1 triple-negative breast cancer cells. The apoptosis of tumor cells after UVC irradiation was verified using resazurin and Annexin V/propidium iodide flow cytometric assays. Protective immunity was achieved in immunized BALB/c mice, showing partial remission. Adoptive transfer of splenocytes or plasma from the mice in remission showed a protective effect in the naive BALB/c mice that received a living 4T1 tumor cell injection. 4T1-specific IgG antibodies were recorded in the plasma of the mice following immunization with the whole-cell vaccine. Interleukin-2 (IL-2) and oligonucleotide 2006 (ODN2006) adjuvants were used for the transfer of splenocytes from C57BL/6 mice into cyclophosphamide-treated BALB/c mice, resulting in prolonged survival, reduced tumor growth, and remission in 33% of the cases, without the development of the graft-versus-host disease. Our approach offers a simple, cost-effective whole-cell vaccine protocol that can be administered to immunocompetent healthy organisms. The plasma or the adoptive transfer of HLA-matching immunized donor-derived leukocytes could be used as an immune cell therapy for cancer patients.

show abstract

Rethinking Antigen Source: Cancer Vaccines Based on Whole Tumor Cell/tissue Lysate or Whole Tumor Cell

Cited by 22 publications

References 235 publications

Recent advances in mRNA‐based vaccine for cancer therapy; bench to bedside

Recent advances in mRNA‐based vaccine for cancer therapy; bench to bedside

Lymph-targeted high-density lipoprotein-mimetic nanovaccine for multi-antigenic personalized cancer immunotherapy

Introduction of an Ultraviolet C-Irradiated 4T1 Murine Breast Cancer Whole-Cell Vaccine Model

Contact Info

Product

Resources

About